Demonstration of immunogenicity with the poorly immunogenic B16 melanoma.

Animal tumors of spontaneous origin have consistently been found to be less immunogenic than are tumors induced by chemical carcinogens or oncogenic viruses. Spontaneous tumors rarely demonstrate significant immunogenicity in classical transplantation rejection tests. This study demonstrates a novel approach to the question of tumor immunogenicity using viable tumor cells in diffusion chambers. Classical transplantation rejection was induced to the poorly immunogenic, spontaneous B16 murine melanoma by implantation of diffusion chambers containing viable B16 melanoma tumor cells. Implantation of B16 chambers i.p. for at least 4 weeks induced specific, long-term resistance to subsequent live B16 tumor cell challenge. In contrast, immunization with irradiated tumor cells for the same time interval resulted in a delay of tumor growth but had no effect on survival. These studies demonstrate the possibility that a significant anti-tumor immune response against the B16 melanoma may be induced without the presence and negative regulatory influences of a progressively growing B16 tumor. In addition, the diffusion chamber sensitization technique may detect the antigenicity of some tumors which are not detectable by classical transplantation rejection tests. Thus, the diffusion chamber technique provides another avenue for testing the immunogenicity of tumors, especially those of spontaneous origin.

[1]  H. Rapp Appropriateness of animal models for the immunology of human cancer. , 1979, Cancer research.

[2]  M. Saier,et al.  Growth of nontumorigenic cells in Millipore diffusion chambers implanted in mice and implications for in vivo growth regulation. , 1979, Cancer research.

[3]  M. H. Tan,et al.  Correlations between the leukocyte adherence inhibition microassay and in vivo tests of transplantation resistance. , 1979, Cancer research.

[4]  U. Kim Factors Influencing Metastasis of Breast Cancer , 1979 .

[5]  H. Hewitt The choice of animal tumors for experimental studies of cancer therapy. , 1978, Advances in cancer research.

[6]  P. Alexander Back to the drawing board—the need for more realistic model systems for immunotherapy , 1977, Cancer.

[7]  R. W. Baldwin Immunological adjuvants in cancer immunotherapy. , 1977, Developments in biological standardization.

[8]  J. Bystryn Release of tumor-associated antigens by murine melanoma cells. , 1976, Journal of immunology.

[9]  M. H. Tan,et al.  Murine colon adenocarcinomas: methods for selective culture in vitro. , 1976, Journal of the National Cancer Institute.

[10]  H. Hewitt,et al.  A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. , 1976, British Journal of Cancer.

[11]  C. Pasqualini,et al.  Growth of sarcoma 180 in splenectomized mice bearing diffusion chambers containing spleen or tumor cells. , 1971, European journal of cancer.

[12]  A. Goldin,et al.  Immunological alteration of leukemic cells in vivo after treatment with an antitumor drug. , 1970, Proceedings of the National Academy of Sciences of the United States of America.

[13]  P. Nettesheim,et al.  Improved diffusion chamber cultures for cytokinetic analysis of antibody response. , 1966, Immunology.

[14]  G. H. Algire,et al.  The diffusion-chamber technique applied to a study of the nature of homograft resistance. , 1954, Journal of the National Cancer Institute.

[15]  G. H. Algire,et al.  Growth of cells in vivo in diffusion chambers. I. Survival of homografts in immunized mice. , 1954, Journal of the National Cancer Institute.